查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813899

美國神經病學臨床試驗市場規模、佔有率和趨勢分析報告：按階段、研究設計、適應症、價值鍊和細分市場預測，2025-2033 年

U.S. Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication, By Indication by Study Design, By Indication by Phase, By Value Chain, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國神經病學臨床試驗市場摘要

預計 2024 年美國神經病學臨床試驗市場價值將達到 25.3 億美元，到 2033 年將達到 44.7 億美元，2025 年至 2033 年的複合年成長率為 6.59%。

美國神經病學臨床試驗市場的成長受到神經科學的重大進步、醫療保健支出的增加以及對複雜神經系統疾病的標靶治療的重視的推動。

推動美國神經病學臨床試驗產業成長的其他因素包括患者意識的提升、對孤兒藥和突破性療法的監管支持，以及對神經病學研發的投入不斷增加。神經退化性疾病的日益流行，加上完善的臨床研究基礎設施，使美國成為神經病學臨床試驗的重要樞紐。此外，來自公共和私營部門的資金，以及製藥公司、委外研發機構(CRO) 和學術機構之間的策略聯盟，在加快試驗進度和提高試驗效率方面發揮關鍵作用，進一步支撐了市場發展。

阿茲海默症、帕金森氏症、多發性硬化症、癲癇和各種罕見神經系統綜合症的盛行率不斷上升，推動了對新型治療方案的需求並增加了臨床試驗的數量。這些研究涵蓋了早期到晚期階段，更先進的項目專注於疾病修正治療、神經保護劑和基於基因的干涉。此外，製藥和生物技術公司正在擴展其內部 CRO 能力，以管理臨床試驗通訊協定、加快執行速度並簡化臨床試驗操作。而且，以神經病學為重點的臨床實驗地點的數量正在增加，從而提高了患者招募的準確性、最佳化了臨床實驗品質並縮短了入組時間。內部能力和地點專業知識的結合正在提高該國神經病學臨床試驗的規模和實施率。

此外，市場參與企業正轉向採用分散式和混合式臨床試驗模式，以實現更廣泛的患者參與和更快的數據收集。此外，先進神經影像技術、基於生物標記的診斷方法以及人工智慧主導的患者選擇工具的日益普及，正在提高試驗的準確性和結果的可預測性。此外，許多生物製藥公司正在擴展其神經病學研究組合和站點網路，以擴大其地理覆蓋範圍，加快監管核准，並更好地滿足醫療資源匱乏地區患者的未滿足需求，從而進一步推動美國神經病學臨床試驗市場的發展。

因此，神經病學臨床試驗市場對美國醫療保健產業至關重要，因為它能夠解決對醫療成本、勞動生產力和患者整體生活品質產生重大影響的病症。此外，這些臨床試驗對於將科學創新轉化為可銷售的治療方法，同時減輕疾病負擔至關重要。預計上述因素將在預計的時間內推動市場發展。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國神經病學臨床試驗市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場挑戰
    • 市場機遇
  • 研發成本分析（2021-2024）
  • 技術格局
  • 定價模式分析
  • 2024年臨床試驗量分析
    • 2024年美國神經學臨床試驗（分階段）總數
    • 2024 年美國神經病學臨床試驗總數（依研究設計）
    • 2024 年美國神經病學臨床試驗總數（按主要適應症分類）
  • 關稅影響分析
  • 價值鏈分析
    • 供應趨勢
    • 需求趨勢
  • 市場分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析

第4章美國神經病學臨床試驗市場：階段估計與趨勢分析

  • 美國神經病學臨床試驗市場（按階段）：細分儀表板
  • 美國神經病學臨床試驗市場（分階段）：波動分析
  • 階段，2021-2033
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章美國神經病學臨床試驗市場：試驗設計評估與趨勢分析

  • 美國神經病學臨床試驗市場（依研究設計）：細分儀表板
  • 美國神經病學臨床試驗市場（依研究設計）：變異分析
  • 按研究設計，2021-2033年
  • 侵入性
  • 觀察
  • 擴展訪問

第6章：美國神經病學臨床試驗市場：適應症估計與趨勢分析

  • 美國神經病學臨床試驗市場（按適應症）：細分儀表板
  • 美國神經病學臨床試驗市場（按適應症）：差異分析
  • 依症狀，2021-2033 年
  • 阿茲海默症
  • 憂鬱症（MDD）
  • 帕金森氏症（PD）
  • 癲癇
  • 中風
  • 創傷性腦損傷（TBI）
  • 肌萎縮側索硬化症（ALS）
  • 亨丁頓舞蹈症
  • 肌肉再生
  • 其他

第7章美國神經病學臨床試驗市場：依研究設計適應症的估計與趨勢分析

  • 美國神經病學臨床試驗市場，按研究設計分類的適應症：細分儀表板
  • 美國神經病學臨床試驗市場，依研究設計分類的適應症：變異分析
  • 按研究設計，2021-2033年
  • 阿茲海默症
    • 阿茲海默症干預
    • 阿茲海默症觀察
    • 阿茲海默症擴大可及性
  • 憂鬱症（MDD）
    • 憂鬱症（MDD）干預
    • 憂鬱症（MDD）觀察
    • 擴大憂鬱症治療途徑（MDD）
  • 帕金森氏症（PD）
    • 帕金森氏症 (PD) 干預
    • 帕金森氏症（PD）觀察
    • 帕金森氏症 (PD) 擴展獲取途徑
  • 癲癇
    • 癲癇干預
    • 癲癇觀察
    • 癲癇擴展准入
  • 中風
    • 中風干預
    • 中風觀察
    • 中風擴展訪問
  • 創傷性腦損傷（TBI）
    • 創傷性腦損傷 (TBI) 干預
    • 創傷性腦損傷（TBI）觀察
    • 創傷性腦損傷 (TBI) 擴展訪問
  • 肌萎縮側索硬化症（ALS）
    • 肌萎縮側索硬化症（ALS）干預
    • 肌萎縮側索硬化症（ALS）觀察性研究
    • 肌萎縮側索硬化症（ALS）擴展獲取途徑
  • 亨丁頓舞蹈症
    • 亨丁頓舞蹈症干預
    • 亨丁頓舞蹈症觀察
    • 擴大亨廷頓舞蹈症的治療範圍
  • 肌肉再生
    • 肌肉再生干預
    • 肌肉再生觀察
    • 擴大肌肉再生途徑
  • 其他
    • 其他干預措施
    • 其他觀察
    • 其他擴展訪問

第 8 章：美國神經病學臨床試驗市場：適應症估計與各階段趨勢分析

  • 美國神經病學臨床試驗市場（按適應症和階段）：細分儀表板
  • 美國神經病學臨床試驗市場（按適應症和階段）：差異分析
  • 階段，2021-2033
  • 阿茲海默症
    • 阿茲海默症第一階段
    • 阿茲海默症2期
    • 阿茲海默症III 期
    • 阿茲海默症IV 期
  • 憂鬱症（MDD）
    • 憂鬱症（MDD）第一階段
    • 憂鬱症（MDD）第二階段
    • 憂鬱症（MDD）III期
    • 憂鬱症（MDD）IV期
  • 帕金森氏症（PD）
    • 帕金森氏症（PD）I期
    • 帕金森氏症 (PD) II 期試驗
    • 帕金森氏症 (PD) III 期試驗
    • 帕金森氏症 (PD) IV 期試驗
  • 癲癇
    • 癲癇1期
    • 癲癇2期
    • 癲癇3期
    • 癲癇IV期
  • 中風
    • 中風第一期
    • 中風 II 期
    • 中風 III 期
    • 中風IV期
  • 創傷性腦損傷（TBI）
    • 創傷性腦損傷 (TBI) 第一期
    • 創傷性腦損傷（TBI）II期
    • 創傷性腦損傷（TBI）III期
    • 創傷性腦損傷（TBI）IV期
  • 肌萎縮側索硬化症（ALS）
    • 肌萎縮側索硬化症（ALS）I期
    • 肌萎縮側索硬化症（ALS）II期
    • 肌萎縮側索硬化症（ALS）3期臨床試驗
    • 肌萎縮側索硬化症（ALS）IV期試驗
  • 亨丁頓舞蹈症
    • 亨廷頓舞蹈症的分期
    • 亨廷頓氏舞蹈症 II 期
    • 亨丁頓舞蹈症 III 期
    • 亨廷頓氏舞蹈症IV期
  • 肌肉再生
    • 肌肉再生第一階段
    • 肌肉再生第二階段
    • 肌肉再生第三階段
    • 肌肉再生第四階段
  • 其他
    • 其他第一階段
    • 其他第二階段
    • 其他第三期
    • 其他 IV 期

第9章美國神經病學臨床試驗市場：價值鏈評估與趨勢分析

  • 美國神經病學臨床試驗市場價值鏈：細分儀表板
  • 美國神經病學臨床試驗市場（價值鏈）：變化分析
  • 按價值鏈分類，2021-2033年
  • 內部
  • CRO
  • 臨床實驗試驗地點/臨床地點

第10章 競爭格局

  • 市場參與企業分類
    • 市場領導
    • 新興企業
  • 2024年市場估值分析（熱圖分析）
  • 公司簡介
    • Syneos Health
    • Icon Plc
    • Lindus Health
    • AbbVie
    • GlaxoSmithKline
    • Labcorp Drug Development
    • Pfizer
    • AstraZeneca
    • Biogen
    • Eli Lilly
    • Alzheon
    • BDD Pharma
Product Code: GVR-4-68040-714-9

U.S. Neurology Clinical Trials Market Summary

The U.S. neurology clinical trials market size was estimated at USD 2.53 billion in 2024 and is projected to reach USD 4.47 billion by 2033, growing at a CAGR of 6.59% from 2025 to 2033. The growth of the U.S. market for neurology clinical trials is driven by significant advancements in neuroscience, increasing healthcare spending, and an emphasis on targeted therapies for intricate neurological conditions.

Other factors driving the growth of the U.S. neurology clinical trials industry include increasing patient awareness, regulatory support for orphan drugs and breakthrough therapies, and rising investment in neurology research and development. The rising incidence of neurodegenerative diseases, supported by a well-established clinical research infrastructure, has established the U.S. as a key center for neurology trials. Furthermore, funding from both public and private sectors and strategic partnerships among pharmaceutical companies, contract research organizations (CROs), and academic institutions have played a crucial role in speeding up study timelines and enhancing trial efficiency, further supporting the market.

The increasing prevalence of Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and various rare neurological syndromes has created an increased need for novel treatment options, resulting in a rise in the number of clinical trial activities. These studies are conducted in early and late stages, with more advanced programs concentrating on disease-modifying therapies, neuroprotective agents, and gene-based interventions. In addition, pharmaceutical and biotechnology companies are expanding in-house CRO capabilities to maintain control over study protocols, enhance execution speed, and increase operational efficiency for clinical trials. Besides, a growing number of investigator sites specializing in neurology are further improving patient recruitment accuracy, optimizing trial quality, and shortening enrollment timelines. This blend of in-house capabilities and specialized site expertise boosts the scale and rate of neurological trial delivery across the country.

Moreover, market trends are shifting towards adopting decentralized and hybrid trial models, allowing for broader patient participation and faster data collection. Further, the growing incorporation of advanced neuroimaging techniques, biomarker-based diagnostics, and AI-driven patient selection tools is enhancing the precision of trials and the predictability of outcomes. Furthermore, numerous biopharmaceutical companies are expanding their neurology research portfolios and site networks to strengthen their geographic reach, accelerate regulatory approvals, and better address the unmet needs of patients in underserved areas, further supporting the U.S. neurology clinical trials market.

Thus, the neurology clinical trials market is crucial to the U.S. healthcare industry, as it tackles conditions that heavily influence healthcare costs, workforce productivity, and patients' overall quality of life. Besides, these trials are essential for converting scientific innovations into market-ready treatments while reducing disease burden. Such aforementioned factors are expected to drive the market over the estimated timeframe.

U.S. Neurology Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. neurology clinical trials market report based onphase, study design, indication, indication by study design, indication by phase, and value chain:

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Interventional
  • Observational
  • Expanded Access
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Alzheimer's Disease
  • Depression (MDD)
  • Parkinson's Disease (PD)
  • Epilepsy
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease
  • Muscle Regeneration
  • Others
  • Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Alzheimer's Disease
    • Interventional
    • Observational
    • Expanded Access
  • Depression (MDD)
    • Interventional
    • Observational
    • Expanded Access
  • Parkinson's Disease (PD)
    • Interventional
    • Observational
    • Expanded Access
  • Epilepsy
    • Interventional
    • Observational
    • Expanded Access
  • Stroke
    • Interventional
    • Observational
    • Expanded Access
  • Traumatic Brain Injury (TBI)
    • Interventional
    • Observational
    • Expanded Access
  • Amyotrophic Lateral Sclerosis (ALS)
    • Interventional
    • Observational
    • Expanded Access
  • Huntington's Disease
    • Interventional
    • Observational
    • Expanded Access
  • Muscle Regeneration
    • Interventional
    • Observational
    • Expanded Access
  • Others
    • Interventional
    • Observational
    • Expanded Access
  • Indication by Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Alzheimer's Disease
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Depression (MDD)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Parkinson's Disease (PD)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Epilepsy
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Stroke
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Traumatic Brain Injury (TBI)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Amyotrophic Lateral Sclerosis (ALS)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Huntington's Disease
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Muscle Regeneration
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Others
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Value Chain Outlook (Revenue, USD Million, 2021 - 2033)
  • In-house
  • CROs
  • Investigator Sites/ Clinical Sites

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Study Design
    • 1.2.2. Indication
    • 1.2.3. Indication by Study Design
    • 1.2.4. Indication by Phase
    • 1.2.5. Value Chain
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
    • 1.7.3. Bottom-Up Analysis
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Neurology Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of neurological diseases such as Alzheimer's disease, epilepsy, and stroke
      • 3.2.1.2. Growing adoption of novel technologies in clinical research
      • 3.2.1.3. Rising number of CROs providing U.S. Neurology Clinical research services
      • 3.2.1.4. Increasing funding for neurological studies by public organizations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Increased associated with U.S. Neurology Clinical studies
      • 3.2.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials
    • 3.2.3. Market Challenges
    • 3.2.4. Market Opportunities
  • 3.3. R&D Spending Analysis (2021-2024)
  • 3.4. Technology Landscape
  • 3.5. Pricing Model Analysis
  • 3.6. Clinical Trial Volume Analysis, 2024
    • 3.6.1. Total Number of U.S. Neurology Clinical Trials, by Phase, 2024
    • 3.6.2. Total Number of U.S. Neurology Clinical Trials, by Study Design, 2024
    • 3.6.3. Total Number of U.S. Neurology Clinical Trials, by Key Indication, 2024
  • 3.7. Tariff Impact Analysis
  • 3.8. Value Chain Analysis
    • 3.8.1. Supply Trends
    • 3.8.2. Demand Trends
  • 3.9. Market Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. U.S. Neurology Clinical Trials Market, By Phase: Segment Dashboard
  • 4.2. U.S. Neurology Clinical Trials Market, By Phase: Movement Analysis
  • 4.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. U.S. Neurology Clinical Trials Market, By Study Design: Segment Dashboard
  • 5.2. U.S. Neurology Clinical Trials Market, By Study Design: Movement Analysis
  • 5.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Study Design, 2021 - 2033 (USD Million)
  • 5.4. Interventional
    • 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Observational
    • 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Expanded Access
    • 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. U.S. Neurology Clinical Trials Market, By Indication: Segment Dashboard
  • 6.2. U.S. Neurology Clinical Trials Market, By Indication: Movement Analysis
  • 6.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
  • 6.4. Alzheimer's Disease
    • 6.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Depression (MDD)
    • 6.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Parkinson's Disease (PD)
    • 6.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Epilepsy
    • 6.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Stroke
    • 6.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Traumatic Brain Injury (TBI)
    • 6.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Amyotrophic Lateral Sclerosis (ALS)
    • 6.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Huntington's Disease
    • 6.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Muscle Regeneration
    • 6.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.13. Others
    • 6.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Neurology Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. U.S. Neurology Clinical Trials Market, Indication by Study Design: Segment Dashboard
  • 7.2. U.S. Neurology Clinical Trials Market, Indication by Study Design: Movement Analysis
  • 7.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • 7.4. Alzheimer's Disease
    • 7.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Alzheimer's Disease Interventional
      • 7.4.2.1. Alzheimer's Disease Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Alzheimer's Disease Observational
      • 7.4.3.1. Alzheimer's Disease Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Alzheimer's Disease Expanded Access
      • 7.4.4.1. Alzheimer's Disease Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Depression (MDD)
    • 7.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Depression (MDD) Interventional
      • 7.5.2.1. Depression (MDD) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Depression (MDD) Observational
      • 7.5.3.1. Depression (MDD) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Depression (MDD) Expanded Access
      • 7.5.4.1. Depression (MDD) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Parkinson's Disease (PD)
    • 7.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Parkinson's Disease (PD) Interventional
      • 7.6.2.1. Parkinson's Disease (PD) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Parkinson's Disease (PD) Observational
      • 7.6.3.1. Parkinson's Disease (PD) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Parkinson's Disease (PD) Expanded Access
      • 7.6.4.1. Parkinson's Disease (PD) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Epilepsy
    • 7.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Epilepsy Interventional
      • 7.7.2.1. Epilepsy Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Epilepsy Observational
      • 7.7.3.1. Epilepsy Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Epilepsy Expanded Access
      • 7.7.4.1. Epilepsy Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Stroke
    • 7.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Stroke Interventional
      • 7.8.2.1. Stroke Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Stroke Observational
      • 7.8.3.1. Stroke Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Stroke Expanded Access
      • 7.8.4.1. Stroke Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Traumatic Brain Injury (TBI)
    • 7.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.2. Traumatic Brain Injury (TBI) Interventional
      • 7.9.2.1. Traumatic Brain Injury (TBI) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.3. Traumatic Brain Injury (TBI) Observational
      • 7.9.3.1. Traumatic Brain Injury (TBI) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.4. Traumatic Brain Injury (TBI) Expanded Access
      • 7.9.4.1. Traumatic Brain Injury (TBI) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Amyotrophic Lateral Sclerosis (ALS)
    • 7.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.2. Amyotrophic Lateral Sclerosis (ALS) Interventional
      • 7.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.3. Amyotrophic Lateral Sclerosis (ALS) Observational
      • 7.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.4. Amyotrophic Lateral Sclerosis (ALS) Expanded Access
      • 7.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Huntington's Disease
    • 7.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.2. Huntington's Disease Interventional
      • 7.11.2.1. Huntington's Disease Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.3. Huntington's Disease Observational
      • 7.11.3.1. Huntington's Disease Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.4. Huntington's Disease Expanded Access
      • 7.11.4.1. Huntington's Disease Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.12. Muscle Regeneration
    • 7.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.12.2. Muscle Regeneration Interventional
      • 7.12.2.1. Muscle Regeneration Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.12.3. Muscle Regeneration Observational
      • 7.12.3.1. Muscle Regeneration Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.12.4. Muscle Regeneration Expanded Access
      • 7.12.4.1. Muscle Regeneration Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.13. Others
    • 7.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.13.2. Others Interventional
      • 7.13.2.1. Others Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.13.3. Others Observational
      • 7.13.3.1. Others Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.13.4. Others Expanded Access
      • 7.13.4.1. Others Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Neurology Clinical Trials Market: Indication by Phase Estimates & Trend Analysis

  • 8.1. U.S. Neurology Clinical Trials Market, Indication by Phase: Segment Dashboard
  • 8.2. U.S. Neurology Clinical Trials Market, Indication by Phase: Movement Analysis
  • 8.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Phase, 2021 - 2033 (USD Million)
  • 8.4. Alzheimer's Disease
    • 8.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. Alzheimer's Disease Phase I
      • 8.4.2.1. Alzheimer's Disease Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Alzheimer's Disease Phase II
      • 8.4.3.1. Alzheimer's Disease Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Alzheimer's Disease Phase III
      • 8.4.4.1. Alzheimer's Disease Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.5. Alzheimer's Disease Phase IV
      • 8.4.5.1. Alzheimer's Disease Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Depression (MDD)
    • 8.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. Depression (MDD) Phase I
      • 8.5.2.1. Depression (MDD) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Depression (MDD) Phase II
      • 8.5.3.1. Depression (MDD) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. Depression (MDD) Phase III
      • 8.5.4.1. Depression (MDD) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Depression (MDD) Phase IV
      • 8.5.5.1. Depression (MDD) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Parkinson's Disease (PD)
    • 8.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Parkinson's Disease (PD) Phase I
      • 8.6.2.1. Parkinson's Disease (PD) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. Parkinson's Disease (PD) Phase II
      • 8.6.3.1. Parkinson's Disease (PD) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. Parkinson's Disease (PD) Phase III
      • 8.6.4.1. Parkinson's Disease (PD) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Parkinson's Disease (PD) Phase IV
      • 8.6.5.1. Parkinson's Disease (PD) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Epilepsy
    • 8.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Epilepsy Phase I
      • 8.7.2.1. Epilepsy Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Epilepsy Phase II
      • 8.7.3.1. Epilepsy Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.4. Epilepsy Phase III
      • 8.7.4.1. Epilepsy Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.5. Epilepsy Phase IV
      • 8.7.5.1. Epilepsy Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Stroke
    • 8.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. Stroke Phase I
      • 8.8.2.1. Stroke Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Stroke Phase II
      • 8.8.3.1. Stroke Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. Stroke Phase III
      • 8.8.4.1. Stroke Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Stroke Phase IV
      • 8.8.5.1. Stroke Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Traumatic Brain Injury (TBI)
    • 8.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.9.2. Traumatic Brain Injury (TBI) Phase I
      • 8.9.2.1. Traumatic Brain Injury (TBI) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.9.3. Traumatic Brain Injury (TBI) Phase II
      • 8.9.3.1. Traumatic Brain Injury (TBI) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.9.4. Traumatic Brain Injury (TBI) Phase III
      • 8.9.4.1. Traumatic Brain Injury (TBI) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.9.5. Traumatic Brain Injury (TBI) Phase IV
      • 8.9.5.1. Traumatic Brain Injury (TBI) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Amyotrophic Lateral Sclerosis (ALS)
    • 8.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.10.2. Amyotrophic Lateral Sclerosis (ALS) Phase I
      • 8.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.10.3. Amyotrophic Lateral Sclerosis (ALS) Phase II
      • 8.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.10.4. Amyotrophic Lateral Sclerosis (ALS) Phase III
      • 8.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.10.5. Amyotrophic Lateral Sclerosis (ALS) Phase IV
      • 8.10.5.1. Amyotrophic Lateral Sclerosis (ALS) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.11. Huntington's Disease
    • 8.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.11.2. Huntington's Disease Phase
      • 8.11.2.1. Huntington's Disease Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.11.3. Huntington's Disease Phase II
      • 8.11.3.1. Huntington's Disease Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.11.4. Huntington's Disease Phase III
      • 8.11.4.1. Huntington's Disease Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.11.5. Huntington's Disease Phase IV
      • 8.11.5.1. Huntington's Disease Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.12. Muscle Regeneration
    • 8.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.12.2. Muscle Regeneration Phase I
      • 8.12.2.1. Muscle Regeneration Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.12.3. Muscle Regeneration Phase II
      • 8.12.3.1. Muscle Regeneration Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.12.4. Muscle Regeneration Phase III
      • 8.12.4.1. Muscle Regeneration Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.12.5. Muscle Regeneration Phase IV
      • 8.12.5.1. Muscle Regeneration Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.13. Others
    • 8.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.13.2. Others Phase I
      • 8.13.2.1. Others Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.13.3. Others Phase II
      • 8.13.3.1. Others Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.13.4. Others Phase III
      • 8.13.4.1. Others Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.13.5. Others Phase IV
      • 8.13.5.1. Others Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. U.S. Neurology Clinical Trials Market: Value Chain Estimates & Trend Analysis

  • 9.1. U.S. Neurology Clinical Trials Market, By Value Chain: Segment Dashboard
  • 9.2. U.S. Neurology Clinical Trials Market, By Value Chain: Movement Analysis
  • 9.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Value Chain, 2021 - 2033 (USD Million)
  • 9.4. In-house
    • 9.4.1. In-house Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. CROs
    • 9.5.1. CROs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Investigator Sites/Clinical Sites
    • 9.6.1. Investigator Sites/Clinical Sites Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Assessment Analysis, 2024 (Heat Map Analysis)
  • 10.3. Company Profiles
    • 10.3.1. Syneos Health
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Icon Plc
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Lindus Health
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. AbbVie
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. GlaxoSmithKline
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Labcorp Drug Development
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Pfizer
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. AstraZeneca
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Biogen
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Eli Lilly
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Alzheon
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. BDD Pharma
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 4 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 5 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 6 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 7 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Phase, 2021 - 2033 (USD Million)
  • Table 8 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Value Chain, 2021 - 2033 (USD Million)"

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. neurology clinical trials market dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. neurology clinical trials market: phase outlook and key takeaways
  • Fig. 20 U.S. neurology clinical trials market: phase movement analysis
  • Fig. 21 Phase I market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Phase II market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Phase III market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Phase IV market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. neurology clinical trials market: study design outlook and key takeaways
  • Fig. 26 U.S. neurology clinical trials market: study design movement analysis
  • Fig. 27 Interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. neurology clinical trials market: indication outlook and key takeaways
  • Fig. 31 U.S. neurology clinical trials market: indication movement analysis
  • Fig. 32 Alzheimer's disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Depression (MDD) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Parkinson's Disease (PD) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Epilepsy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Stroke market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Traumatic Brain Injury (TBI) Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Huntington's disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Muscle Regeneration Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. neurology clinical trials market: Indication by study design outlook and key takeaways
  • Fig. 43 U.S. neurology clinical trials market: Indication by study design movement analysis
  • Fig. 44 Alzheimer's disease interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Alzheimer's disease observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Alzheimer's disease expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Depression (MDD) interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Depression (MDD) observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Depression (MDD) expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Parkinson's Disease (PD) interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Parkinson's Disease (PD) observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Parkinson's Disease (PD) expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Epilepsy interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Epilepsy observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Epilepsy expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Stroke interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Stroke observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Stroke expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Traumatic Brain Injury (TBI) interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Traumatic Brain Injury (TBI) observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Traumatic Brain Injury (TBI) expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Amyotrophic Lateral Sclerosis (ALS) interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Amyotrophic Lateral Sclerosis (ALS) observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Amyotrophic Lateral Sclerosis (ALS) expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Huntington's disease interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Huntington's disease observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Huntington's disease expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Muscle regeneration interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Muscle regeneration observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Muscle regeneration expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Others interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Others observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Others expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 U.S. neurology clinical trials market: value chain design outlook and key takeaways
  • Fig. 75 U.S. neurology clinical trials market: value chain movement analysis
  • Fig. 76 In-house market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 CROs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Investigator sites/clinical sites market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key company categorization
  • Fig. 80 Service heat map analysis
  • Fig. 81 Strategic framework